Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, LB-100, Reported to be a Potentiator of Immunotherapy in an Animal Mo...
April 17 2017 - 9:45AM
Marketwired
EAST SETAUKET, NY-(Marketwired - Apr 17, 2017) - Lixte
Biotechnology Holdings, Inc. (OTCQB: LIXT) presented a
late-breaking abstract entitled "Protein phosphatase 2A inhibition
with a novel small molecule inhibitor, LB-100, achieves durable
immune-mediated antitumor activity when combined with PD-1 blockade
in a preclinical model" as a poster (abstract number LB-193) at the
American Association for Cancer Research (AACR) Annual Meeting 2017
in Washington, DC on April 4th. This research was done in
collaboration with scientists at the National Institute of
Neurological Disorders and Stroke (NINDS), NIH.
Dr. John S. Kovach, CEO of Lixte, said, "The study shows that in
an animal model Lixte's lead clinical compound, LB-100 has
synergistic potential in conjunction with immune checkpoint
blockade supporting investigation of its ability to enhance
immunotherapy in the clinic.
LB-100, a novel, first-in-class, small molecule inhibitor of
protein phosphatase 2A (PP2A), recently completed a Phase 1 trial
in patients with advanced cancer (Chung 2016). In that trial,
LB-100, was well tolerated at doses associated with stabilization
of progressive solid tumors in 10 of 21 patients with receiving 2
or more courses of treatment. One patient with previously
refractory pancreatic cancer had a partial regression for 11
months."
Dr. Kovach continued, "Based on a number of published
preclinical studies, we had expected that LB-100 will be
therapeutically useful primarily as a potentiator of cytotoxic
anti-cancer drugs and x-ray. The present study, however, raises the
possibility that, in addition, LB-100 may have a role in enhancing
the efficacy of so-called 'immune checkpoint blockers' - agents
that allow patients' own immune system to attack their own
cancers."
About Lixte Biotechnology Holdings, Inc.
Lixte is a drug
discovery company that uses biomarker technology to identify enzyme
targets associated with serious common diseases and then design
novel compounds to attack those targets. Lixte's product pipeline
encompasses two major categories of compounds at various stages of
pre-clinical and clinical development that the Company believes
have broad therapeutic potential not only for cancer but also for
other debilitating and life-threatening diseases.
Forward-Looking Statements
This announcement contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, and Section 21E of the Securities Exchange
Act of 1934. For example, statements regarding the Company's
financial position, business strategy and other plans and
objectives for future operations, and assumptions and predictions
about future product demand, supply, manufacturing, costs,
marketing and pricing factors are all forward-looking statements.
These statements are generally accompanied by words such as
"intend," anticipate," "believe," "estimate," "potential(ly),"
"continue," "forecast," "predict," "plan," "may," "will," "could,"
"would," "should," "expect" or the negative of such terms or other
comparable terminology. The Company believes that the assumptions
and expectations reflected in such forward-looking statements are
reasonable, based on information available to it on the date
hereof, but the Company cannot provide assurances that these
assumptions and expectations will prove to have been correct or
that the Company will take any action that the Company may
presently be planning. However, these forward-looking statements
are inherently subject to known and unknown risks and
uncertainties. Actual results or experience may differ materially
from those expected or anticipated in the forward-looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to, regulatory policies,
available cash, research results, competition from other similar
businesses, and market and general economic factors. This
discussion should be read in conjunction with the Company's filings
with the United States Securities and Exchange Commission at
http://www.sec.gov/edgar.shtml.
Additional information on the Company is available at
www.lixte.com.
Contact info:
eforman@lixte.com
(631) 830-7092